MADRIGAL PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| ExhibitNumber · Exhibit Description · Incorporated by Reference · FiledHerewith | |||||
|---|---|---|---|---|---|
| 10.1# | First Amendment to the Research, Development and Commercialization Agreement, dated as of January 29, 2026, by and between the Registrant and Roche. | Form 8-K (Exhibit 10.1) | 1/30/2026 | 001-33277 | |
| 10.2* | Severance and Change of Control Agreement, dated as of February 18, 2026, by and between the Registrant and Carole Huntsman. | Form 10-K (Exhibit 10.31) | 2/19/2026 | 001-33277 | |
| 10.3* | Severance and Change of Control Agreement, dated as of February 18, 2026, by and between the Registrant and Mardi Dier. | Form 10-K (Exhibit 10.33) | 2/19/2026 | 001-33277 | |
| 10.4* | Severance and Change of Control Agreement, dated as of February 18, 2026, by and between the Registrant and Shannon Kelley. | Form 10-K (Exhibit 10.35) | 2/19/2026 | 001-33277 | |
| 10.5* | Severance and Change of Control Agreement, dated as of February 18, 2026, by and between the Registrant and David Soergel, M.D. | Form 10-K (Exhibit 10.37) | 2/19/2026 | 001-33277 | |
| 10.6 | Amendment to Lease, dated March 14, 2026, by and between KPG FF Owner, L.P. and the Registrant. | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1** | Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | |||
| 104 | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |
Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
- Indicates a management contract, compensatory plan or arrangement.
**The certifications attached as Exhibit 32.1 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.